These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 17219733

  • 21. Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients.
    Wirden M, Lambert-Niclot S, Marcelin AG, Schneider L, Ait-Mohand H, Brunet C, Angleraud F, Amard S, Katlama C, Calvez V.
    AIDS; 2009 Jan 02; 23(1):95-9. PubMed ID: 19050391
    [Abstract] [Full Text] [Related]

  • 22. Antiretroviral resistance testing for clinical management.
    Youree BE, D'Aquila RT.
    AIDS Rev; 2002 Jan 02; 4(1):3-12. PubMed ID: 11998782
    [Abstract] [Full Text] [Related]

  • 23. The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens.
    Maggiolo F, Ripamonti D, Torti C, Arici C, Antinori A, Quiros-Roldan E, Minoli L, Sighinolfi L, Nasta P, Suter F, MASTER Data Base Cohort.
    Antivir Ther; 2006 Jan 02; 11(7):923-9. PubMed ID: 17302255
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Mechanism of HIV antiretroviral drugs progress toward drug resistance.
    Ammaranond P, Sanguansittianan S.
    Fundam Clin Pharmacol; 2012 Feb 02; 26(1):146-61. PubMed ID: 22118474
    [Abstract] [Full Text] [Related]

  • 30. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
    Soria A, Porten K, Fampou-Toundji JC, Galli L, Mougnutou R, Buard V, Kfutwah A, Vessière A, Rousset D, Teck R, Calmy A, Ciaffi L, Lazzarin A, Gianotti N.
    Antivir Ther; 2009 Feb 02; 14(3):339-47. PubMed ID: 19474468
    [Abstract] [Full Text] [Related]

  • 31. [Research on the selective kinetics of HIV-1 nucleoside reverse transcriptase inhibitor drug resistance-associated mutations among 4 AIDS patients receiving highly active antiretroviral therapy].
    Li J, Jiao LY, Li HP, Li L, Liu YJ, Zhuang DM, Liu SY, Bao ZY, Li H, Wang Z, Li JY.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Aug 02; 29(8):794-800. PubMed ID: 19103117
    [Abstract] [Full Text] [Related]

  • 32. Update on HIV resistance and resistance testing.
    Sebastian J, Faruki H.
    Med Res Rev; 2004 Jan 02; 24(1):115-25. PubMed ID: 14595674
    [Abstract] [Full Text] [Related]

  • 33. Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.
    Mathiesen S, Dam E, Roge B, Joergensen LB, Laursen AL, Gerstoft J, Clavel F.
    Antivir Ther; 2007 Jan 02; 12(3):335-43. PubMed ID: 17591023
    [Abstract] [Full Text] [Related]

  • 34. Surveillance of genotypic resistance mutations in chronic HIV-1 treated individuals after completion of the National Access to Antiretroviral Program in Thailand.
    Sukasem C, Churdboonchart V, Chasombat S, Kohreanudom S, Watitpun C, Pasomsub E, Piroj W, Tiensuwan M, Chantratita W.
    Infection; 2007 Apr 02; 35(2):81-8. PubMed ID: 17401711
    [Abstract] [Full Text] [Related]

  • 35. Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine.
    Ntemgwa M, Wainberg MA, Oliveira M, Moisi D, Lalonde R, Micheli V, Brenner BG.
    Antimicrob Agents Chemother; 2007 Nov 02; 51(11):3861-9. PubMed ID: 17724152
    [Abstract] [Full Text] [Related]

  • 36. Drug resistance. Navigating resistance pathways.
    Kuritzkes D.
    AIDS Read; 2002 Sep 02; 12(9):395-400, 407. PubMed ID: 12402803
    [Abstract] [Full Text] [Related]

  • 37. Profile of drug resistance mutations among HIV-1-infected Tunisian subjects failing antiretroviral therapy.
    Jlizi A, Ben Ammar El Gaaied A, Slim A, Tebourski F, Ben Mamou M, Ben Chaabane T, Letaief-Omezzine A, Chakroun M, Garbouj M, Ben Rejeb S.
    Arch Virol; 2008 Sep 02; 153(6):1103-8. PubMed ID: 18483694
    [Abstract] [Full Text] [Related]

  • 38. Primary drug resistance in antiretroviral-naïve injection drug users.
    Tossonian HK, Raffa JD, Grebely J, Viljoen M, Mead A, Khara M, McLean M, Krishnamurthy A, DeVlaming S, Conway B.
    Int J Infect Dis; 2009 Sep 02; 13(5):577-83. PubMed ID: 19111493
    [Abstract] [Full Text] [Related]

  • 39. Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes.
    Holguín A, Ramirez de Arellano E, Rivas P, Soriano V.
    AIDS Rev; 2006 Sep 02; 8(2):98-107. PubMed ID: 16848277
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.